Home › Compare › TBGNF vs BTI

TBGNF vs BTI: Dividend Comparison 2026

TBGNF yields 1176.47% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TBGNF wins by $78814195.16M in total portfolio value
10 years
TBGNF
TBGNF
● Live price
1176.47%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78814195.20M
Annual income
$67,523,701,253,088.38
Full TBGNF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — TBGNF vs BTI

📍 TBGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTBGNFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TBGNF + BTI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TBGNF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TBGNF
Annual income on $10K today (after 15% tax)
$100,000.00/yr
After 10yr DRIP, annual income (after tax)
$57,395,146,065,125.13/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, TBGNF beats the other by $57,395,146,062,756.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TBGNF + BTI for your $10,000?

TBGNF: 50%BTI: 50%
100% BTI50/50100% TBGNF
Portfolio after 10yr
$39407097.62M
Annual income
$33,761,850,627,937.51/yr
Blended yield
85.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

TBGNF
No analyst data
Altman Z
-23.0
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TBGNF buys
0
BTI buys
0
No recent congressional trades found for TBGNF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTBGNFBTI
Forward yield1176.47% ✓5.38%
Annual dividend / share$2.00$3.15 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3% ✓
Portfolio after 10y$78814195.20M ✓$37.7K
Annual income after 10y$67,523,701,253,088.38 ✓$2,786.64
Total dividends collected$77969765.27M ✓$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: TBGNF vs BTI ($10,000, DRIP)

YearTBGNF PortfolioTBGNF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$128,347$117,647.06$11,299$598.92+$117.0K → TBGNF
2$1,548,514$1,411,182.61$12,794$703.91+$1.54M → TBGNF
3$17,569,052$15,912,142.01$14,518$829.07+$17.55M → TBGNF
4$187,523,354$168,724,468.35$16,513$978.64+$187.51M → TBGNF
5$1,883,716,681$1,683,066,692.55$18,827$1,157.84+$1883.70M → TBGNF
6$17,816,329,317$15,800,752,468.33$21,518$1,373.12+$17816.31M → TBGNF
7$158,731,384,105$139,667,911,735.60$24,657$1,632.46+$158731.36M → TBGNF
8$1,332,782,916,056$1,162,940,335,063.89$28,329$1,945.74+$1332782.89M → TBGNF
9$10,551,863,503,163$9,125,785,782,982.70$32,637$2,325.33+$10551863.47M → TBGNF
10$78,814,195,201,473$67,523,701,253,088.38$37,708$2,786.64+$78814195.16M → TBGNF

TBGNF vs BTI: Complete Analysis 2026

TBGNF — Stock

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Full TBGNF Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this TBGNF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TBGNF vs SCHDTBGNF vs JEPITBGNF vs OTBGNF vs KOTBGNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.